When was Ancilia founded?

Ancilia was founded in 2019 and raised its 1st funding round 2 years after it was founded.

Where is Ancilia located?

Ancilia is headquartered in New York City, United States.

How many employees does Ancilia have?

As of Aug 31, 2026, the latest employee count at Ancilia is 21.

Is Ancilia a funded company?

Ancilia is a funded company, having raised a total of $14.3M across 6 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jul 15, 2021.

When was the latest funding round of Ancilia?

Ancilia's latest funding was a $***** Series B round on Feb 13, 2026, with participation from 0 investor. Its primary sector is Immunology. In United States, the Immunology sector has seen $4.27B in funding in 2026 to date.

Where does Ancilia rank among its competitors?

Ancilia ranks 1613th amongst 3789 active competitors, of which 1245 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Ancilia?

Ancilia's top competitors include Jazz Pharmaceuticals, BeiGene and Biogen. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Ancilia - 2026 Company Profile, Funding & Competitors

Company Details

Developer of microbiome therapies for immunology and oncology indications. It offers bacterial therapeutics that target the viral components of the microbiome to treat chronic diseases. The therapies are based on CRISPR technology that enhances bacterial immunity against viruses and modulates the human microbiome.

Website: www.anciliabio.com/
Email ID: *****@anciliabio.com

Key Metrics

Founded Year

2019

Location

New York City, United States

Stage

Series B

Total Funding

$14.3M in 6 rounds

Latest Funding Round

Series B, Feb 13, 2026, $*****

Investors

Safar Partners & 8 more

Ranked

1613^th among 3789 active competitors

Employee Count

21 as on Aug 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3529 more

View Ancilia's full profile

Ancilia has raised a total funding of $14.3M over 6 rounds. Its first funding round was on Jul 15, 2021. Ancilia has 9 institutional investors.

Here is the list of recent funding rounds of Ancilia:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 13, 2026	6241347	Series B	1799251	6884334	2725687	2578387
Aug 14, 2025	4781970	Grant (prize money)	4637622	7316277	4789775	HHS
Jul 23, 2025	8544963	Grant (prize money)	6468606	8743878	9987185	HHS

Access funding benchmarks and valuations. Sign up today!

View details of Ancilia's funding rounds and investors

Ancilia's employee count trend

Ancilia has 21 employees as of Aug 26. Here is Ancilia's employee count trend over the years:

Uncover Ancilia's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Ancilia include Jazz Pharmaceuticals, BeiGene and Biogen. Here is the list of Top 10 competitors of Ancilia, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
4th	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
5th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
6th	Novozymes 2000, Bagsvaerd (Denmark), Acquired	Developer of biosolutions and enzymes for multiple industries and applications of biotechnology	$9.75M	DOE, CHV & 3 others	73/100
7th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
8th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Leaps by Bayer, New Enterprise Associates ... & 30 others	72/100
9th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
10th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
1613th	Ancilia 2019, New York City (United States), Series B	Developer of microbiome therapies for immunology and oncology indications	$14.3M	MBX Capital, Metaplanet & 7 others	34/100